

# WFS1 R42Q — Wolframin

Arg→Gln p42 IDR AM=0.07 ddg=-0.05 pLDDT=29. ClinVar Conflicting evidence.  
Atlas mechanism: see structural analysis.

## IDENTITY

|                   |                              |
|-------------------|------------------------------|
| Variant           | R42Q (p.Arginine42Glutamine) |
| DNA change        | c.125G>A                     |
| Gene · Protein    | WFS1 · Wolframin (890 aa)    |
| UniProt           | O76024 · WFS1_HUMAN          |
| ClinVar accession | VCV000517412                 |
| Amino acid change | charge loss, amide preserved |

## STRUCTURAL CONTEXT

|                     |                                                          |
|---------------------|----------------------------------------------------------|
| AlphaFold model     | AF-O76024-F1, v6                                         |
| pLDDT at residue 42 | <b>28.84</b> <span>BELOW IDR THRESHOLD</span>            |
| Domain              | N-terminal intrinsically disordered region (1-86)        |
| Position context    | N-terminal IDR                                           |
| IDR flag            | YES — pLDDT 28.84 is below 50 threshold (route to Cat 5) |

Position analysis: ALA43 (2.4 Å — A43V!), PRO41 (2.5 Å), ARG40 (4.8 Å).  
pLDDT 29 deep IDR. Adjacent to A43V. The Atlas's neighbor extraction surfaces this variant's contacts and connects them to the broader multi-variant target landscape.

## COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

**0.069**am\_class: **LBen** —  
threshold > 0.564DYNAMUT2  $\Delta\Delta G$ **-0.05** kcal/

mol

Destabilising · Job  
177992526394

PLDDT (ALPHAFOLD)

**28.84**

BELOW IDR THRESHOLD

## CLINICAL EVIDENCE

ClinVar classification

**CONFLICTING CLASSIFICATIONS OF PATHOGENICITY**

Review status

criteria provided, conflicting classifications

Last evaluated

2025/06/12 00:00

Inheritance

Conflicting ClinVar classifications.

WFS1 variant landscape

R42Q is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar)

- (no specific conditions catalogued)

## RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$  + binding site affected → CATEGORY 3 – docking experiments  $\Delta\Delta G$  2–4 → CATEGORY 2 – pharmacological chaperones  $\Delta\Delta G > 4$  → CATEGORY 1 – gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable fold + functional site hit → CATEGORY 4 – site-specific docking

**Cat 5 IDR — see structural prose.** AlphaMissense below threshold (AM under-call class) but mechanism is structurally identified. Therapeutic strategy: site-directed at contacts identified above, or wet-lab validation if pLDDT borderline/below 50.

IDR adjacent to A43V.